See the DrugPatentWatch profile for Zolpidem
The DrugBank accession number for zolpidem tartrate is DB00421.
What is zolpidem tartrate?
Zolpidem tartrate is a non-benzodiazepine hypnotic agent used for the short-term treatment of insomnia [1]. It acts as a sedative and is commonly prescribed to help individuals fall asleep [2]. The drug is available in various dosage forms, including immediate-release and extended-release tablets [1].
How does zolpidem tartrate work?
Zolpidem tartrate functions by binding to specific sites on the gamma-aminobutyric acid (GABA) receptor complex, similar to benzodiazepines, but with a more selective action [1][2]. This binding enhances the inhibitory effects of GABA in the brain, leading to sedation and facilitating sleep [2].
When does the patent for zolpidem tartrate expire?
Information regarding the specific patent expiry dates for zolpidem tartrate is available through resources that track drug patents and exclusivity [3]. DrugPatentWatch.com provides detailed patent information for pharmaceutical products, which would include data on zolpidem tartrate [3].
What are the common side effects of zolpidem tartrate?
Common side effects associated with zolpidem tartrate include drowsiness, dizziness, headache, and nausea [1]. More serious, though less common, side effects can include complex sleep behaviors such as sleepwalking or sleep-driving, hallucinations, and memory problems [1][2].
Are there alternative treatments for insomnia?
Yes, several alternative treatments exist for insomnia, including other prescription medications, over-the-counter sleep aids, and non-pharmacological approaches [4]. Cognitive behavioral therapy for insomnia (CBT-I) is a widely recommended first-line treatment [4]. Other prescription options may include different classes of hypnotics or medications targeting underlying causes of insomnia [4].
How does zolpidem tartrate compare to benzodiazepines for insomnia?
While both zolpidem tartrate and benzodiazepines are used to treat insomnia, zolpidem tartrate is considered a non-benzodiazepine hypnotic with a more selective action on GABA receptors [1][2]. This selectivity is intended to reduce some of the side effects associated with traditional benzodiazepines, such as muscle relaxation and anti-anxiety effects [1]. However, both classes of drugs carry risks of dependence and withdrawal [2].
Who manufactures zolpidem tartrate?
Zolpidem tartrate is manufactured by various pharmaceutical companies, as it is available in generic forms [1]. Brand names such as Ambien were among the first available, with many other manufacturers producing generic versions following patent expirations [1][3].
What is the regulatory status of zolpidem tartrate?
Zolpidem tartrate is approved by regulatory agencies like the U.S. Food and Drug Administration (FDA) for the treatment of insomnia [1]. Due to the potential for abuse and dependence, it is classified as a controlled substance in many countries [2].
What clinical data supports the use of zolpidem tartrate?
Clinical trials have demonstrated the efficacy of zolpidem tartrate in reducing sleep latency (the time it takes to fall asleep) and improving sleep maintenance [1][2]. These studies have also assessed its safety profile and identified common side effects [1].
What are patient concerns regarding zolpidem tartrate?
Patients often express concerns about the potential for dependence and withdrawal symptoms associated with zolpidem tartrate [2]. Additionally, awareness of potential side effects like next-day drowsiness, memory impairment, and the risk of complex sleep behaviors are significant patient considerations [1][2].
Can zolpidem tartrate be used for long-term insomnia treatment?
Zolpidem tartrate is generally recommended for short-term treatment of insomnia due to the risk of developing tolerance and dependence with prolonged use [1][2]. For chronic insomnia, alternative treatments or a comprehensive management plan are typically advised [4].
What are the risks of zolpidem tartrate overdose?
An overdose of zolpidem tartrate can lead to severe central nervous system depression, potentially resulting in significant drowsiness, confusion, respiratory depression, and coma [1]. Immediate medical attention is required in cases of suspected overdose [1].
Sources:
[1] https://go.drugbank.com/drugs/DB00421
[2] https://www.ncbi.nlm.nih.gov/books/NBK513309/
[3] https://drugpatentwatch.com/
[4] https://www.nccih.nih.gov/health/insomnia-and-complementary-health-approaches